Clinical trial NCT02795988: A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Official title: A Phase 1b/2 Open-Label Study With Randomization in Phase 2 of IMU-131 HER2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Gastrointestinal Neoplasms
Adenocarcinoma
Keywords: Secondary
Lead sponsor: Imugene Limited
Sponsor class: INDUSTRY
First posted: 2016-06-10
Enrollment: 64
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131. The RP2D will be evaluated in the dose expansion Phase 2 study. The Phase 2 study is a randomized, open label comparison of IMU-131 plus standard of care chemotherapy versus standard of care chemotherapy alone.


Eligibility criteria: Inclusion Criteria:

1. Patient has been informed of the investigational nature of this study and has given written informed consent in accordance with institutional, local, and national guidelines;
2. Age ≥ 20 years old;
3. Life expectancy of at least 12 weeks;
4. Phase 1b: No prior chemotherapy or radiotherapy for advanced gastric or GEJ cancer within 6 months prior to Day 0; Phase 2: No prior chemotherapy or radiotherapy for advanced gastric or GEJ cancer within 3 months prior to Day 0;
5. Metastatic gastric or GEJ adenocarcinoma, or locally advanced disease not amenable to surgical resection;
6. HER2/neu overexpression (3+ by immunohistochemistry (IHC) or if IHC 2+ confirmed by fluorescent in situ hybridization \[FISH\] or chromogenic in situ hybridization \[CISH\]). Patients with IHC 2+ expression without confirmation of overexpression by fluorescent in situ hybridization \[FISH\] or chromogenic in situ hybridization \[CISH\]) may be included in Phase 1b with agreement of Imugene Limited;
7. Phase 1b: ECOG performance status 0-1; Phase 2: ECOG performance status 0-2;
8. At least one measurable lesion as defined by RECIST 1.1 criteria. Patients with non-measurable lesions may be included in Phase1b with agreement of Imugene Limited;
9. Adequate left ventricular ejection function at baseline, defined as LVEF \> 50% by echocardiogram or MUGA scan (Multi Gated Acquisition Scan);
10. Adequate hematologic function: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL;
11. Adequate liver function evidenced by bilirubin ≤ 1.5 x laboratory upper limit of normal \[ULN\], and ALT and AST ≤ 3 x laboratory ULN if no liver involvement or ALT and AST ≤ 5 times laboratory ULN with liver involvement;
12. Adequate renal function (creatinine ≤ 1.5 x laboratory ULN);
13. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
14. Male and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment (see section 4.3 for details). A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.

Exclusion Criteria:

1. Previous treatment with trastuzumab or any other HER2/neu targeting antibody or agent;
2. Continuous systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment. Inhaled or topical steroids and physiological replacement doses of up to 10 mg daily prednisone equivalents are permitted in the absence of active auto-immune disease;
3. Prior organ transplant;
4. Phase 1b: Patient not considered a candidate for 5-FU, capecitabine, or cisplatin chemotherapy; Phase 2: Patient not considered a candidate for 5-FU, capecitabine, cisplatin or oxaliplatin chemotherapy;
5. History of documented congestive heart failure; angina pectoris requiring antianginal medication; evidence of transmural infarction on ECG; poorly controlled hypertension; clinically significant valvular heart disease; high risk uncontrolled arrhythmias; or New York Heart Association (NYHA) class II heart disease;
6. If on warfarin (Coumadin®) or other vitamin K antagonists;
7. Concurrent active malignancy except for adequately controlled limited basal cell carcinoma of the skin;
8. Peripheral neuropathy or hearing loss of NCI CTCAE Grade \> 2;
9. History of uncontrolled seizures, central nervous disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent, participation in the study, or adversely affecting compliance to study drugs;
10. Active infection requiring IV antibiotics;
11. Positive for human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active hepatitis B (HBsAg reactive) or active hepatitis C (HCV ribonucleic acid \[RNA\] qualitative) infection;
12. Pregnant or lactating females;
13. Major surgery within 4 weeks prior to study entry. Minor surgery (excluding diagnostic biopsy) within 1 week prior to study entry;
14. Has received a live-virus vaccination within 4 weeks of first study vaccination. Seasonal flu vaccines that do not contain live virus are permitted;
15. Current or recent (within 4 weeks of first IMU-131 vaccination) treatment with another investigational drug or participation in another investigational study.
16. Phase 2: Patients with a known diphtheria toxoid hypersensitivity.

Primary outcomes:
measure: Phase 1b: Number of Participants With Adverse Events (AEs)
timeFrame: Up to approximately 7 months
measure: Phase 2: Overall Survival (OS)
timeFrame: Up to approximately 30 months
measure: Phase 2 Extension: Number of Participants With AEs
timeFrame: From date of first dose to date of last dose plus 30 days (Up to 24 months)
Secondary outcomes:
measure: Phase 2 and Phase 2 Extension: Progression-Free Survival (PFS)
timeFrame: Up to approximately 30 months
measure: Phase 2 and Phase 2 Extension: Time to Progression (TTP)
timeFrame: Up to approximately 30 months
measure: Phase 2 and Phase 2 Extension: Disease Control Rate (DCR)
timeFrame: Up to approximately 30 months
measure: Phase 2 and Phase 2 Extension: Objective Response Rate (ORR)
timeFrame: Up to approximately 30 months
measure: Phase 2 and Phase 2 Extension: Duration of Response (DOR)
timeFrame: Up to approximately 30 months
measure: Phase 2 and Phase 2 Extension: Percentage Change From Baseline in Tumor Size
timeFrame: Baseline up to approximately 30 months
measure: Phase 2 Extension: OS
timeFrame: Up to 24 months
Other outcomes:
Locations:
city: Tbilisi
country: Georgia
facility: ARENSIA Exploratory Medicine LLC
city: Vijayawada
country: India
facility: City Cancer Center
state: Andhra Pradesh
city: Guwahati
country: India
facility: North East Cancer Hospital and Research Institute
state: Assam
city: Bengaluru
country: India
facility: Shetty's Hospital
state: Karnataka
city: Nashik
country: India
facility: Curie Manavata Cancer Centre
state: Maharashtra
city: Pune
country: India
facility: Deenanath Mangeshkar Hospital and Research Centre
state: Maharashtra
city: Bangalore
country: India
facility: Victoria Hospital
city: Hyderabad
country: India
facility: MNJ Institute of Oncology and Regional Cancer Centre
city: Kolkata
country: India
facility: Tata Medical Centre
city: Nagpur
country: India
facility: HCG NCHRI Cancer Centre
city: Patna
country: India
facility: Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
city: Chisinau
country: Moldova, Republic of
facility: ARENSIA Exploratory Medicine IMSP Institutul Oncologic
city: Sremska Kamenica
country: Serbia
facility: Oncology Institute of Vojvodina
state: Južnobanatski Okrug
city: Belgrade
country: Serbia
facility: Institute for Oncology and Radiology of Serbia - PPDS
city: Belgrade
country: Serbia
facility: Military Medical Academy
city: Belgrade
country: Serbia
facility: Clinical Hospital Center Bezanijska Kosa
city: Tainan
country: Taiwan
facility: National Cheng-Kung University Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Hat Yai
country: Thailand
facility: Division of Medical Oncology, Department of Medicine, Prince of Songkla University, Songklanagarind Hospital
state: Songkhla Province
city: Bangkok
country: Thailand
facility: National Cancer Institute of Thailand
city: Chiang Mai
country: Thailand
facility: Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University
city: Kapitanivka
country: Ukraine
facility: ARENSIA Exploratory Medicine LLC
Study officials:
References:
citation: Wiedermann U, Garner-Spitzer E, Chao Y, Maglakelidze M, Bulat I, Dechaphunkul A, Arpornwirat W, Charoentum C, Yen CJ, Yau TC, Tanasanvimon S, Maneechavakajorn J, Sookprasert A, Bai LY, Chou WC, Ungtrakul T, Drinic M, Tobias J, Zielinski CC, Chong L, Ede NJ, Marino MT, Good AJ. Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001. Clin Cancer Res. 2021 Jul 1;27(13):3649-3660. doi: 10.1158/1078-0432.CCR-20-3742. Epub 2021 Apr 20.